By Michael Atkins, MD and Evan Lipson, MD
A series of four videos:
Ep. 1: Dr. Evan Lipson (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine) provides a brief overview of metastatic melanoma, including information on incidence and prognosis. He also covers the current state of biomarker testing for patients recently diagnosed with metastatic melanoma.
Ep. 2: Dr. Michael Atkins (Georgetown University Medical Center) and Dr. Lipson introduce and discuss a patient with unresectable stage IV metastatic melanoma.
Ep. 3: Dr. Atkins and Dr. Lipson review data from the practice-changing DREAMseq (EA6134) trial, which evaluated nivolumab plus ipilimumab, in treatment-naïve patients with BRAFV600-mutated melanoma.
Ep. 4: Dr. Atkins and Dr. Lipson discuss the use of BRAF and MEK inhibitors as first-line treatments for patients with metastatic melanoma.